Is Abeona Therapeutics (ABEO) Inc a good buy right now?

Abeona Therapeutics Inc is a preliminary-stage biopharmaceutical organization, which takes part in the advancement of quality treatment for extreme and dangerous intriguing sicknesses. The firm operated in the healthcare sector. The market capitalization of ABEO is $36.73 million and has its headquarters in New York. The stock of Abeona Therapeutics trades under the symbol of “ABEO” and has a current trading price of $0.24 per unit.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Business Overview

Abeona Therapeutics Inc creates cell and quality treatments for dangerous uncommon hereditary infections. Their lead clinical program is EB-101, an autologous, quality amended cell treatment for passive dystrophic epidermolysis bullosa (“RDEB”), which is as of now in the vital Phase 3 VITAL clinical preliminary. Abeona is at the very front of cell and quality treatment innovative work. They are a completely coordinated organization highlighting treatments in clinical turn of events, in-house fabricating offices, a powerful pipeline, and logical and clinical initiative. Their main goal is to attempt to make, create, fabricate, and convey cell and quality treatments for individuals affected by genuine sicknesses.

ABEO joins forces with driving scholastic scientists, patient support associations, guardians, and other biotechnology organizations to foster treatments that address the hidden reason for a wide range of intriguing hereditary illnesses for which no compelling treatment choices exist today.

ABEO News

ABEO has been the subject of various ongoing examination reports. StockNews started inclusion on Abeona Therapeutics in an examination report on Tuesday. They set a “hold” rating for the organization. Zacks Investment Research redesigned Abeona Therapeutics from a “hold” rating to a “buy” rating and set a price target of $0.25 for the organization in an exploration report on 5 April. Two investigators have evaluated the stock with a hold rating and three have doled out a purchase rating to the organization. As per MarketBeat, the organization at present has an agreement rating of “buy” and an agreed price target of $1.75.

Various mutual funds and other institutional financial backers have as of late added to or diminished their stakes in the firm. Virtu Financial LLC purchased another stake in Abeona Therapeutics in the final quarter esteemed at about $84,000. Millinium Management LLC developed its stake in Abeona Therapeutics by 20.3% in the final quarter. D. E. Shaw and Co. Inc. obtained another situation in Abeona Therapeutics in the final quarter esteemed at about $0.849 million. At long last, Point72 Asset Management L.P. procured another situation in the final quarter esteemed at about $1.078 million. Institutional financial backers and flexible investments own 27.03% of the organization’s stock.

Abeona Therapeutics (ABEO) last posted its quarterly performance information in March 2022. The biopharmaceutical organization revealed a loss of $0.45 per stock for the quarter. The business had an income of $3 million during the term. The total loss of the company was $46 million in the final quarter.